Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 979
Source of Programmatic Cabotegravir for PrEP Supply
The first supplies of CAB for programmatic use (as opposed to use in implementation studies) began to arrive in countries in 2024. Currently, 16 countries are rolling out CAB for programmatic use, with the majority of supply provided by PEPFAR, and some additional quantities procured by the Global Fund.
Lenacapavir Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of November 2025.
Prevention Option:
HIV Prevention R&D at Risk
AVAC’s analysis of the impact of US Government funding cuts, terminated projects, and other policy changes on the HIV prevention research and development (R&D) pipeline, and on HIV research broadly.
Global Health Watch Timeline
This timeline tracks selected milestone events in 2025, both massive disruptions in global health along with advocacy responses and wins in the midst of madness.
Preparing for LEN
In the first year since efficacy results were reported, LEN for PrEP has achieved critical milestones in record time compared to oral PrEP, the dapivirine vaginal ring, and injectable cabotegravir. Speed, scale, and equity are still needed to deliver impact.
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
An Overview of Lenacapavir for PrEP Trials
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.
Prevention Option:
Sexually Transmitted Infections: ‘Self-testing’ versus ‘self-collection’: the critical role of consistent language in the field of STI diagnostics
This editorial from AVAC’s Alison Footman and colleagues makes the case for precise and consistent language around self-testing and self-collection. because clarity impacts policy, expectations, and access.
Prevention Option:
Moving a Product to the Real World
To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.
Prevention Option:
The HIV Prevention Pipeline
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
Prevention Option:
showing 1-10 of 979